Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.41 |
| ▸ | USP2 | O75604 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30724390 | 0.84 | CYP2D6 (0.37) | CYP2D6USP2CYP1A2TSHRCYP3A4 | |
| SCHEMBL3629869 | 0.81 | CCR5 (0.33) | CYP1A2 | |
| SCHEMBL1133674 | 0.79 | CYP2D6 (0.34) | CYP2D6USP2CYP1A2TSHRCYP3A4 | |
| SCHEMBL2084825 | 0.79 | PHGDH (0.32) | — | |
| SCHEMBL16834077 | 0.79 | CCR5 (0.35) | USP2CYP1A2ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL31180099 | 0.77 | CCR5 (0.34) | USP2CYP1A2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL20137491 | 0.77 | CCR5 (0.34) | USP2CYP1A2SMN1; SMN2 | |
| SCHEMBL522388 | 0.76 | ALDH1A1 (0.36) | CYP2C9ALDH1A1MEN1KMT2A | |
| SCHEMBL71979 | 0.75 | SOS1 (0.33) | ALDH1A1 | |
| SCHEMBL3844090 | 0.75 | KMT2A (0.33) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093501-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
| WO-2009037168-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093501-A1 | Heterocyclic antiviral compounds | CCR5, CCR1, CCR2 | CYP2D6 925/4885USP2 4041/4885CYP1A2 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.